Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875702 | 1.00 | TSHR (0.36) | TSHRALDH1A1KIF11HTTTK1 | |
| SCHEMBL11296399 | 0.84 | NPSR1 (0.36) | TSHRALDH1A1KIF11TK1DUT | |
| SCHEMBL18011761 | 0.84 | NPSR1 (0.36) | TSHRALDH1A1KIF11TK1DUT | |
| SCHEMBL8036817 | 0.84 | SMN1; SMN2 (0.38) | TSHRALDH1A1TK1KDM4EMEN1 | |
| SCHEMBL2619884 | 0.84 | SMN1; SMN2 (0.38) | TSHRALDH1A1TK1KDM4EMEN1 | |
| SCHEMBL21764294 | 0.82 | PTPN1 (0.38) | ALDH1A1KIF11HTTALOX15MEN1 | |
| SCHEMBL11027048 | 0.82 | PTPN1 (0.38) | ALDH1A1KIF11HTTALOX15MEN1 | |
| SCHEMBL15818117 | 0.81 | KIF11 (0.37) | TSHRALDH1A1KIF11TK1DUT | |
| SCHEMBL2619910 | 0.81 | MEN1 (0.43) | TSHRALDH1A1KIF11HTTTK1 | |
| SCHEMBL11027709 | 0.80 | CES2 (0.35) | KIF11DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288949-B1 | TETRAHYDROFURANE-FUSED AMINOHYDROTHIAZINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3262051-B1 | SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190231791-A1 | Combination Therapy | LILLY CO ELI (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190106434-A1 | N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2019-04-11 | — | — | US | disclosed |
| EP-3458461-A1 | N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL]-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE | Eli Lilly and Company (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10011610-B2 | Selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3288949-A1 | TETRAHYDROFURANE-FUSED AMINOHYDROTHIAZINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Eli Lilly and Company (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3262051-A1 | SELECTIVE BACE1 INHIBITORS | Eli Lilly and Company (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017200863-A1 | N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL]-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9522923-B2 | Selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-20 | — | — | US | disclosed |
| WO-2016137788-A1 | SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244465-A1 | SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY | 2016-08-25 | — | — | US | disclosed |
| EP-2233474-B1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2653473-A1 | Fused Aminodihydro-Oxazine Derivatives | Eisai R&D Management Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2456774-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2233474-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106434-A1 | N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | TSHR 3865/4885ALDH1A1 138/4885KIF11 2534/4885 |
| US-10011610-B2 | Selective BACE1 inhibitors | BACE1, BACE2, APP | TSHR 4639/4885ALDH1A1 1323/4885KIF11 2810/4885 |
| US-20160244465-A1 | SELECTIVE BACE1 INHIBITORS | BACE1, BACE2, APP | TSHR 4639/4885ALDH1A1 2024/4885KIF11 2823/4885 |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | TSHR 3087/4885ALDH1A1 3053/4885KIF11 3550/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | TSHR 3997/4885ALDH1A1 2468/4885KIF11 3580/4885 |
| US-20190231791-A1 | Combination Therapy | PSEN2, PSEN1, FCGRT | TSHR 1165/4885ALDH1A1 3279/4885KIF11 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.